Journal
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
Volume 28, Issue 5, Pages 379-384Publisher
ELSEVIER
DOI: 10.1016/j.ijantimicag.2006.09.001
Keywords
hospital-acquired MRSA; costs
Ask authors/readers for more resources
For most countries badly affected by methicillin-resistant Staphylococcus aureus (MRSA) there have been many years of debate about its relative virulence compared with methicillin-susceptible S. aureus (MSSA) and whether it could be controlled. Now that it is endemic in the majority of hospitals around the world, it is clear that it is at least as virulent as MSSA and is an additional burden of healthcare-acquired infection. There is increasing evidence that, despite this endemicity, control efforts can be successful, although they are often perceived as expensive. In reality, there is a large body of consistent evidence that control is highly cost effective, particularly in the context of the huge societal costs of MRSA and the future ever-greater threats that it poses. (c) 2006 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available